Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
6997 | 1418 | 43.4 | 85% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
419 | 3 | ADENOVIRUS//MERKEL CELL CARCINOMA//GENE THERAPY | 28518 |
564 | 2 | GENE THERAPY//ADENOVIRUS//HUMAN GENE THERAPY | 14456 |
6997 | 1 | MOL MED GENE THER Y UNIT//ADENOVIRUS//HELPER DEPENDENT ADENOVIRAL VECTOR | 1418 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | MOL MED GENE THER Y UNIT | address | 393648 | 2% | 63% | 29 |
2 | ADENOVIRUS | authKW | 299224 | 19% | 5% | 265 |
3 | HELPER DEPENDENT ADENOVIRAL VECTOR | authKW | 204146 | 1% | 59% | 16 |
4 | HELPER DEPENDENT ADENOVIRUS | authKW | 201855 | 1% | 63% | 15 |
5 | GUTLESS | authKW | 174411 | 1% | 90% | 9 |
6 | HUMAN GENE THERAPY | journal | 167455 | 11% | 5% | 161 |
7 | HELPER DEPENDENT | authKW | 165629 | 1% | 77% | 10 |
8 | ADENOVIRUS VECTOR | authKW | 149934 | 4% | 11% | 61 |
9 | GENE THERAPY | journal | 115684 | 10% | 4% | 145 |
10 | GUTLESS ADENOVIRUS | authKW | 107662 | 0% | 100% | 5 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Medicine, Research & Experimental | 14201 | 37% | 0% | 531 |
2 | Biotechnology & Applied Microbiology | 13554 | 41% | 0% | 588 |
3 | Genetics & Heredity | 10846 | 37% | 0% | 519 |
4 | Virology | 4644 | 14% | 0% | 200 |
5 | Biochemistry & Molecular Biology | 705 | 22% | 0% | 313 |
6 | Biochemical Research Methods | 182 | 5% | 0% | 67 |
7 | Immunology | 144 | 7% | 0% | 95 |
8 | Transplantation | 131 | 2% | 0% | 34 |
9 | Neurosciences | 112 | 8% | 0% | 111 |
10 | Cell Biology | 77 | 6% | 0% | 84 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | MOL MED GENE THER Y UNIT | 393648 | 2% | 63% | 29 |
2 | MT STATES MED | 48446 | 0% | 75% | 3 |
3 | MOL CELLULAR ENGN | 45962 | 1% | 11% | 19 |
4 | MEDGENE THER EUT | 43065 | 0% | 100% | 2 |
5 | NEUROMUSCULAR GRP | 33671 | 1% | 12% | 13 |
6 | LIBIN GENE THER Y UNIT | 32296 | 0% | 50% | 3 |
7 | FERMENTAT CELL CULTURE | 31315 | 0% | 36% | 4 |
8 | HUMAN GENE THER Y | 24919 | 2% | 4% | 28 |
9 | ABT F MOL MED VIROL | 21532 | 0% | 100% | 1 |
10 | ANIM MED SURG SECT | 21532 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | HUMAN GENE THERAPY | 167455 | 11% | 5% | 161 |
2 | GENE THERAPY | 115684 | 10% | 4% | 145 |
3 | MOLECULAR THERAPY | 32308 | 5% | 2% | 73 |
4 | JOURNAL OF GENE MEDICINE | 16637 | 2% | 2% | 33 |
5 | CURRENT GENE THERAPY | 5635 | 1% | 2% | 12 |
6 | JOURNAL OF VIROLOGY | 5536 | 7% | 0% | 102 |
7 | HUMAN GENE THERAPY METHODS | 3233 | 0% | 3% | 5 |
8 | CURRENT OPINION IN MOLECULAR THERAPEUTICS | 1980 | 1% | 1% | 9 |
9 | CANCER GENE THERAPY | 1561 | 1% | 1% | 12 |
10 | CYTOTECHNOLOGY | 1200 | 1% | 1% | 11 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | ADENOVIRUS | 299224 | 19% | 5% | 265 | Search ADENOVIRUS | Search ADENOVIRUS |
2 | HELPER DEPENDENT ADENOVIRAL VECTOR | 204146 | 1% | 59% | 16 | Search HELPER+DEPENDENT+ADENOVIRAL+VECTOR | Search HELPER+DEPENDENT+ADENOVIRAL+VECTOR |
3 | HELPER DEPENDENT ADENOVIRUS | 201855 | 1% | 63% | 15 | Search HELPER+DEPENDENT+ADENOVIRUS | Search HELPER+DEPENDENT+ADENOVIRUS |
4 | GUTLESS | 174411 | 1% | 90% | 9 | Search GUTLESS | Search GUTLESS |
5 | HELPER DEPENDENT | 165629 | 1% | 77% | 10 | Search HELPER+DEPENDENT | Search HELPER+DEPENDENT |
6 | ADENOVIRUS VECTOR | 149934 | 4% | 11% | 61 | Search ADENOVIRUS+VECTOR | Search ADENOVIRUS+VECTOR |
7 | GUTLESS ADENOVIRUS | 107662 | 0% | 100% | 5 | Search GUTLESS+ADENOVIRUS | Search GUTLESS+ADENOVIRUS |
8 | GENE THERAPY | 102452 | 18% | 2% | 262 | Search GENE+THERAPY | Search GENE+THERAPY |
9 | ADENOVIRAL VECTOR | 93350 | 4% | 8% | 55 | Search ADENOVIRAL+VECTOR | Search ADENOVIRAL+VECTOR |
10 | GUTLESS VECTORS | 76899 | 0% | 71% | 5 | Search GUTLESS+VECTORS | Search GUTLESS+VECTORS |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | DORMOND, E , PERRIER, M , KAMEN, A , (2009) FROM THE FIRST TO THE THIRD GENERATION ADENOVIRAL VECTOR: WHAT PARAMETERS ARE GOVERNING THE PRODUCTION YIELD?.BIOTECHNOLOGY ADVANCES. VOL. 27. ISSUE 2. P. 133-144 | 96 | 85% | 21 |
2 | PALMER, DJ , NG, P , (2005) HELPER-DEPENDENT ADENOVIRAL VECTORS FOR GENE THERAPY.HUMAN GENE THERAPY. VOL. 16. ISSUE 1. P. 1-16 | 75 | 84% | 99 |
3 | SEGURA, MM , ALBA, R , BOSCH, A , CHILLON, M , (2008) ADVANCES IN HELPER-DEPENDENT ADENOVIRAL VECTOR RESEARCH.CURRENT GENE THERAPY. VOL. 8. ISSUE 4. P. 222-235 | 94 | 65% | 29 |
4 | SILVA, AC , PEIXOTO, C , LUCAS, T , KUPPERS, C , CRUZ, PE , ALVES, PM , KOCHANEK, S , (2010) ADENOVIRUS VECTOR PRODUCTION AND PURIFICATION.CURRENT GENE THERAPY. VOL. 10. ISSUE 6. P. 437-455 | 91 | 62% | 8 |
5 | SCHAGEN, FHE , OSSEVOORT, M , TOES, REM , HOEBEN, RC , (2004) IMMUNE RESPONSES AGAINST ADENOVIRAL VECTORS AND THEIR TRANSGENE PRODUCTS: A REVIEW OF STRATEGIES FOR EVASION.CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. VOL. 50. ISSUE 1. P. 51-70 | 107 | 54% | 60 |
6 | ALBA, R , BOSCH, A , CHILLON, M , (2005) GUTLESS ADENOVIRUS: LAST-GENERATION ADENOVIRUS FOR GENE THERAPY.GENE THERAPY. VOL. 12. ISSUE . P. S18-S27 | 73 | 65% | 103 |
7 | COTS, D , BOSCH, A , CHILLON, M , (2013) HELPER DEPENDENT ADENOVIRUS VECTORS: PROGRESS AND FUTURE PROSPECTS.CURRENT GENE THERAPY. VOL. 13. ISSUE 5. P. 370-381 | 75 | 58% | 4 |
8 | PARKS, RJ , EVELEGH, CM , GRAHAM, FL , (1999) USE OF HELPER-DEPENDENT ADENOVIRAL VECTORS OF ALTERNATIVE SEROTYPES PERMITS REPEAT VECTOR ADMINISTRATION.GENE THERAPY. VOL. 6. ISSUE 9. P. 1565 -1573 | 60 | 87% | 79 |
9 | VETRINI, F , NG, P , (2011) LIVER-DIRECTED GENE THERAPY WITH HELPER-DEPENDENT ADENOVIRAL VECTORS: CURRENT STATE OF THE ART AND FUTURE CHALLENGES.CURRENT PHARMACEUTICAL DESIGN. VOL. 17. ISSUE 24. P. 2488-2499 | 72 | 52% | 10 |
10 | HITT, MM , GRAHAM, FL , (2000) ADENOVIRUS VECTORS FOR HUMAN GENE THERAPY.ADVANCES IN VIRUS RESEARCH, VOL 55. VOL. 55. ISSUE . P. 479-505 | 77 | 58% | 51 |
Classes with closest relation at Level 1 |